3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
2
Endocrine
1
Conditions
Neuroendocrine Tumors
7
Neoplasms
7
Thyroid Neoplasms
6
Thyroid Cancer, Papillary
6
Neoplasms by Site
5
Head and Neck Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Breast Neoplasms
5
Thyroid Diseases
4
Thoracic Neoplasms
4
Sarcoma
4
Respiratory Tract Neoplasms
4
Respiratory Tract Diseases
4
Lung Neoplasms
4
Lung Diseases
4
Endocrine System Diseases
4
Endocrine Gland Neoplasms
4
Colonic Neoplasms
4
Carcinoma, Bronchogenic
4
Bronchial Neoplasms
4
Salivary Gland Neoplasms
3
Pheochromocytoma
3
Paraganglioma
3
Colorectal Neoplasms
3
Central Nervous System Neoplasms
3
Carcinoma, Medullary
3
Neuroectodermal Tumors
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Histologic Type
2
Multiple Endocrine Neoplasia Type 1
2
Interventions
ribociclib
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Breast Diseases
×
Endocrine
×
Clear all
NCT02422615
2023-11-30
MONALEESA-3
Novartis
Phase 3
Completed
726 enrolled
17 charts
1 FDA